QLT QLTI
-
QLT's CEO Discusses QLT091001 Presentation at ARVO (Transcript)
QLT Inc. ( QLTI ) QLT091001 Presentation at ARVO Call May 10, 2012 11:30 am ET Executives ..... Operator Hello. This is the Chorus Call Conference operator. Welcome to the QLT , Inc. conference call and webcast. As a reminder, all participants are …
-
QLT's Pipeline Remains on Track While Competitive Pressures Mount
QLT QLTI reported 1% revenue growth and an operating loss of nearly $11.8 million ..... products like Lucentis and Eylea will maintain a tough headwind for Visudyne. QLT 's orphan drug molecule for retinitis pigmentosa and Leber congenital amaurosis …
-
QLT's CEO Discusses Q1 2012 Results - Earnings Call Transcript
QLT , Inc. ( QLTI ) Q1 2012 Earnings Call May 3, 2012, 8 ..... Call Conference operator. Welcome to the QLT , Inc. First Quarter 2012 conference ..... Good morning, everyone, and welcome to QLT ’s first quarter 2012 earnings conference …
-
Shedding A Little Light On Under-Followed DUSA Pharmaceuticals
By Stephen Simpson : There are certain dusty corners of biopharma where most investors just don't look all that often, and eye care and skin care are high on the list. While the addressable markets are well short of what investors expect from areas like oncology or autoimmune disease, the relative
-
7 Biotech Stocks Being Snapped Up By Insiders
By Kapitall : Do you like getting the inside scoop on your favorite companies? One idea on how to get an inside peek is by considering insider buying. Company insiders report when they buy company stock, and this is viewed very positively by the market. We ran a screen on the biotech industry for
-
QLT's CEO Presents at 30th Annual JPMorgan Healthcare Conference - Conference Call Transcript
QLT , Inc. ( QLTI ) 30th Annual JPMorgan Healthcare Conference Call January 11, 2012 11 ..... long and busy week. So we're glad you could be here to learn about the QLT story. The story over the past six years during my tenure as CEO hasn …
-
QLT ( QLTI ) announces positive preliminary results from a trial on its QLT091001 drug. The treatment aims to help repair vision following genetic eye diseases.
QLT ( QLTI ) announces positive preliminary results from a trial on its QLT091001 drug. The treatment aims to help repair vision following genetic eye diseases. Post your comment!
-
QLT's CEO Discusses Q4 2011 Results - Earnings Call Transcript
QLT , Inc. ( QLTI ) Q4 2011 Earnings Results Conference February ..... Call conference operator. Welcome to the QLT Inc. Fourth Quarter and Year-End 2011 ..... Good morning, everyone. And welcome to QLT ’s fourth quarter and year-end 2011 …
-
QLT ( QLTI ): Q4 EPS of $0.04 may not be comparable to consensus of by -$0.20. Revenue of $11M (+10.4% Y/Y) in-line. (PR)
QLT ( QLTI ): Q4 EPS of $0.04 may not be comparable to consensus of by -$0.20. Revenue of $11M (+10.4% Y/Y) in-line. ( PR ) Post your comment!
-
QLT's Outlook may Improve on Initial Trial Results due in 2012
… change our fair value estimate for QLT QLTI after the company's fourth-quarter ..... 2012 guidance met our expectations. QLT reported 10.4% year-over-year ..... amaurosis and retinitis pigmentosa. QLT will release trial results for both …